Eli Lilly and Company News - September 2026
Eli Lilly's EloraTZP Delivers 23.3% Weight Loss in Phase 2b Trial
Eli Lilly reported positive results from a Phase 2b trial of EloraTZP, an investigational combination of eloralintide and tirzepatide. The trial enrolled 367...
Eli Lilly Says Foundayo Outperformed Novo's Oral Semaglutide in Indirect Comparison
Eli Lilly announced new data suggesting its oral GLP-1 drug Foundayo (orforglipron) provided greater weight loss and blood sugar control than Novo Nordisk's...
Eli Lilly Captures 70% of New Senior Obesity Drug Market Following Medicare Coverage
Eli Lilly CEO Dave Ricks announced that 700,000 seniors have started GLP-1 obesity treatments since Medicare began covering the drugs in July 2026. The company...
Eli Lilly breaks ground on $6.5B Texas plant for weight-loss drugs
Eli Lilly and Company officially broke ground on a $6.5 billion manufacturing campus at Generation Park in Houston, Texas. The project represents the largest...
Eli Lilly traded tariff protection for higher overseas prices in secret deals
A Washington Post investigation revealed secret drug-pricing deals between the Trump administration and Eli Lilly. The agreements reportedly offered Eli Lilly...
Eli Lilly unveils retatrutide data, reporting 20.8% weight loss in diabetes trial
Eli Lilly and Company will present new cardiometabolic data at the European Association for the Study of Diabetes (EASD) 2026 meeting. The presentations...